Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI)
· seekingalpha.com
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough. Click here to read why TRVI stock is a Buy.
My bull case for Trevi Therapeutics ( TRVI ) rests on more than the size of the chronic cough market. The company plans to use the concentrated specialty market...